Felzartamab Biosimilar – Anti-CD38 mAb – Research Grade

Description of Felzartamab Biosimilar - Anti-CD38 mAb - Research Grade

Felzartamab Biosimilar: A Promising Anti-CD38 mAb for Therapeutic Targeting

Felzartamab Biosimilar is a novel monoclonal antibody (mAb) targeting CD38, a cell surface protein that is highly expressed on multiple myeloma (MM) cells. This biosimilar is a research grade version of the original Felzartamab, which has shown promising results in clinical trials for the treatment of MM.

Structure of Felzartamab Biosimilar

Felzartamab Biosimilar is a humanized IgG1 kappa mAb, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, linked by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains of Felzartamab Biosimilar are responsible for binding to the CD38 protein on MM cells.

The amino acid sequence of Felzartamab Biosimilar is highly similar to that of the original Felzartamab, with only a few differences in the constant regions. This biosimilar has been engineered to have a high binding affinity for CD38, while also reducing the risk of immunogenicity and improving stability.

Activity of Felzartamab Biosimilar

Felzartamab Biosimilar exerts its activity by binding to CD38 on the surface of MM cells, leading to a cascade of events that ultimately result in cell death. CD38 is a multifunctional protein that plays a crucial role in the survival and proliferation of MM cells. It is involved in the regulation of intracellular calcium levels, as well as the production of adenosine, a molecule that promotes tumor growth and immune suppression.

By binding to CD38, Felzartamab Biosimilar blocks these functions, leading to a decrease in intracellular calcium and adenosine levels, and ultimately inducing cell death through various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This makes Felzartamab Biosimilar a potent and specific therapeutic agent for the treatment of MM.

Application of Felzartamab Biosimilar

Felzartamab Biosimilar is currently being evaluated in clinical trials for the treatment of MM. It has shown promising results in preclinical studies, with high potency and selectivity for CD38-expressing cells. In a phase I clinical trial, Felzartamab Biosimilar demonstrated a favorable safety profile and preliminary efficacy in patients with relapsed or refractory MM. It is also being investigated in combination with other therapies, such as lenalidomide and dexamethasone, to further enhance its anti-tumor activity.

Beyond MM, CD38 is also expressed on other hematological malignancies, such as acute myeloid leukemia and chronic lymphocytic leukemia, as well as solid tumors, including prostate cancer and breast cancer. This suggests that Felzartamab Biosimilar may have potential applications in other types of cancer, making it a promising candidate for future research and development.

Conclusion

Felzartamab Biosimilar is a research grade version of the original Felzartamab, a novel anti-CD38 mAb with promising results in the treatment of MM. Its structure, activity, and application make it a highly specific and potent therapeutic agent for targeting CD38-expressing cells. Further clinical trials will provide valuable insights into its efficacy and safety, and may lead to its approval for the treatment of MM and other types of cancer.